Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 4/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3972862 | 0.82 | BCHE (0.60) | BCHECYP1A2CYP2A6SLC6A2SLC6A4 | |
| SCHEMBL20021997 | 0.81 | BCHE (0.83) | BCHECYP1A2CYP2A6SLC6A2SLC6A4 | |
| SCHEMBL14024617 | 0.80 | SIGMAR1 (0.54) | BCHECYP1A2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3971600 | 0.80 | SIGMAR1 (0.52) | BCHECYP1A2CYP2A6SIGMAR1HTR2A | |
| SCHEMBL14149518 | 0.80 | SIGMAR1 (0.63) | BCHECYP1A2CYP2A6SLC6A2SLC6A4 | |
| SCHEMBL12153268 | 0.80 | BCHE (0.56) | BCHECYP1A2CYP2A6SLC6A2SLC6A4 | |
| SCHEMBL16256948 | 0.78 | BCHE (0.74) | BCHECYP1A2CYP2A6SLC6A2SLC6A4 | |
| SCHEMBL11791177 | 0.78 | LTA4H (0.50) | BCHECYP1A2SLC6A2SLC6A3SIGMAR1 | |
| SCHEMBL15701699 | 0.77 | CYP1A2 (0.53) | CYP1A2SLC6A2SLC6A4SLC6A3SIGMAR1 | |
| SCHEMBL15701707 | 0.76 | TSHR (0.50) | PYCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346795-B2 | Substituted sulfonamides useful as antiapoptotic Bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-24 | — | — | US | disclosed |
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BCL2, BAX, BCL2A1 | BCHE 4103/4885CYP1A2 4423/4885CYP2A6 3328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.